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Abstract
Malignant peripheral nerve sheath tumors (MPNST) are rare, highly aggressive sarcomas
that can occur spontaneously or from pre-existing plexiform neurofibromas in neurofibroma-
tosis type1 (NF1) patients. MPNSTs have high local recurrence rates, metastasize easily,
are generally resistant to therapeutic intervention and frequently fatal for the patient. Novel
targeted therapeutic strategies are urgently needed. Standard treatment for patients pre-
senting with advanced disease is doxorubicin based chemotherapy which inhibits the
actions of the enzyme topoisomerase IIα (TOP2A). Recent molecular studies using murine
models and cell lines identified the bromodomain containing protein 4 (BRD4) and enhancer
of zeste homolog 2 (EZH2) as novel targets for MPNST treatment. We investigated the
expression and potential use of BRD4, EZH2 and TOP2A as therapeutic targets in human
NF1-derived MPNSTs. The transcript levels of BRD4, EZH2 and TOP2A were determined
in paired formalin-fixed paraffin-embedded (FFPE) neurofibroma/MPNST samples derived
from the same NF1 patient and in a set of plexiform neurofibromas, atypical neurofibromas
and MPNST. We further examined the effect on cell viability of genetic or pharmacological
inhibition of BRD4, EZH2 and TOP2A in an MPNST cell line panel. Our results indicated
that in MPNST samples BRD4 mRNA levels were not upregulated and that MPNST cell
lines were relatively insensitive to the bromodomain inhibitor JQ1. We corroborated that
EZH2 mRNA expression is increased in MPNST but failed to confirm its reported pivotal role
in MPNST pathogenesis as EZH2 knockdown by siRNA did not interfere with cellular prolif-
eration and viability. Finally, the relation between TOP2A levels and sensitivity for doxorubi-
cin was examined, confirming reports that TOP2A mRNA levels were overexpressed in
MPNST and showing that MPNST cell lines exhibited relatively high TOP2A protein levels
and sensitivity to doxorubicin. We tentatively conclude that the potential for effective thera-
peutic intervention in MPNST by targeting BRD4, EZH2 and TOP2A individually, may be
limited. Clinical studies are necessary to ultimately prove the relevance of BRD4 and EZH2
inhibition as novel therapeutic strategies for MPNST.
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Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder which has a de novo inci-
dence of one in 3000 individuals [1–3]. This genetic disorder is caused by defects in the NF1
gene located on chromosome 17q11.2. The NF1 gene encodes a tumor suppressor called neu-
rofibromin 1, which through its GTPase-activating protein (GAP) domain negatively regulates
Ras signaling keeping cell proliferation in check. Inherited or sporadic mutations of NF1
and the partial inactivation of neurofibromin, lead to an increased risk of developing various
tumors. Almost all NF1 patients develop cutaneous neurofibromas and in many patients plexi-
form neurofibromas cause additional morbidity. All tumors exhibit biallelic inactivation of the
NF1 gene and consequently activated signaling through the Ras pathway driving cancer forma-
tion [1, 4]. Plexiform neurofibromas may transform into malignant peripheral nerve sheath
tumors (MPNST), the most common malignancy occuring in NF1 patients, at an incidence
of 2% and a lifetime risk of 8–13% [5]. MPNSTs are classified in the group of the soft tissue
sarcomas (STS) and comprise approximately 5–10% of all STS. MPNST are a class of highly
aggressive and clinically challenging sarcomas. High local recurrence rates, early metastasis
and resistance to chemotherapy are common clinical phenotypes in this cancer. When metas-
tasized, patients face a poor prognosis with only a limited number of systemic chemotherapeu-
tic agents available [6, 7]. Of these, doxorubicin is probably the most active one, targeting—
through intercalation into the DNA—the activity of the enzym topoisomerase IIα (TOP2A)
[8]. Transcriptome data analyses have shown that TOP2A was among the most upregulated
genes in MPNSTs when compared to benign neurofibromas [9, 10]. However, despite the high
expression of TOP2A, advanced MPNST patients do not respond well to doxorubicin given a
2 year overall survival rate of approximately 20%, which is roughly equivalent to the outcome
of patients with metastatic STS other than MPNST [7]. This poor outcome clearly underscores
the need to get better insight into the exact relationship between TOP2A expression and doxo-
rubicin sensitivity in MPNST and the necessity to reveal new leads for treatment.
A better understanding of the pathobiology of MPNST may lead to the identification of
novel treatment targets. Recently, Patel et al. reported the upregulation of Brd4 mRNA and
protein levels in a newly developed murine MPNST model [11, 12] based on transplantation
of Nf1-/-,P53-/- skin-derived precursor cells into nerves of athymic nude mice [13]. Further
investigations inferred a critical role for Brd4 in MPNST pathogenesis as inhibition by shRNAs
or by JQ1, a small molecule BET (bromodomain and extraterminal domain) inhibitor, severely
impaired in vitro growth and in vivo tumorigenesis [13]. It was demonstrated that inhibition
of Brd4 induced expression of the pro-apoptotic molecule Bim leading to apoptosis in MPNST
cells. The BET subfamily of bromodomain proteins to which BRD4 belongs has a role in regulat-
ing transcription by RNA polymerase II. The best studied member BRD4 recruits transcriptional
regulatory complexes to acetylated chromatin and modulates transcriptional elongation of essen-
tial genes involved in cell cycle and apoptosis [14]. In addition, also enhancer of zeste homolog 2
(EZH2) was found upregulated in MPNST compared to neurofibroma and normal nerves [15].
EZH2 is a core element of the polycomb repressive complex 2 (PRC2) a well-known epigenetic
modulator of gene expression [16] and is frequently found overexpressed in malignancies or
mutated in lymphomas [17]. EZH2 involvement in MPNST pathogenesis was demonstrated by
the transient EZH2 knockdown using si/shRNA or EZH2 inhibition by 3-deazaneplanocin A
causing cell cycle arrest and apoptosis in MPNST cells [15, 18]. Evidence is provided for the exis-
tence of a novel signaling pathway in MPNST that mediates the effects of EZH2 via miR-30a/30d
to karoypherin (importin) beta 1 (KPNB1) [15, 18]. Both EZH2 and BRD4 can be targeted by
selective and potent small molecule inhibitors [19, 20] that are currently being evaluated in clini-
cal trials making them appealing targets for the treatment of MPNST.
BRD4, EZH2 and TOP2A in MPNST
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To further investigate the potential role as treatment targets of the above-mentioned pro-
teins, we investigated the expression level of the target genes in FFPE and fresh frozen sample
sets of plexiform neurofibromas and MPNSTs as well as neurofibroma and MPNST cell lines
in order to validate the obtained results from the previous studies.
Materials and methods
Patients and samples
From the Erasmus MC patient files, nine neurofibroma type 1 patients were selected of which
resected plexiform neurofibroma material was present and who developed MPNST. Archival for-
malin-fixed paraffin-embedded (FFPE) tumor samples of both plexiform neurofibroma and
MPNST from the same patient (paired samples) were recovered from the Erasmus MC tissue
bank. Fresh frozen samples from plexiform neurofibroma (n = 11), atypical neurofibroma (n = 4)
and MPNST (n = 7) were also obtained from the Erasmus MC tissue bank. The FFPE and fresh
frozen sample sets do not overlap and were derived from distinct patients. All patients and tumor
characteristics are listed in Table 1. For the histopathological diagnosis of MPNST, atypical neu-
rofibroma and plexiform neurofibroma criteria were used as described before [21, 22] in accor-
dance with the 2016 WHO classification of Tumours of the Central Nervous System [23].
In short, for the diagnosis of MPNST we used morphological criteria (presence of spindle
cells with indistinct cytoplasmic margins and wavy or S-shaped nuclei, arranged in fascicles
with alternating cellular and myxoid areas). Immunostaining for S100 was used for identifica-
tion of a Schwann cell component in the tumors. Atypical neurofibroma was defined by the
presence of mitotic figures, and/or cytological atypia, and/or increased cellularity. The combi-
nation of all three features, however, defined low grade MPNST. Plexiform neurofibroma
involved multiple nerve fascicles and lacked the above mentioned atypical features. Prior to
our research the Daily Board of the Medical Ethics Committee Erasmus MC of Rotterdam,
The Netherlands, reviewed the research proposal. As a result of this review, the Committee
decided that the rules laid down in the Medical Research Involving Human Subjects Act do
not apply to this research (MEC-2016-213).
Cell culture
Human MPNST cell lines ST88-14, 90-8TL, T265 (NF1-associated MPNST) and STS26T (spo-
radic MPNST) were kindly provided by Dr. Eduard Serra (Institute of Predictive and Personal-
ized Medicine of Cancer/IMPPC, Barcelona, Spain). sNF96.2 and HS53.T were obtained from
the ATCC and derived from an NF1-associated MPNST and a cutaneous, NF1-derived, neuro-
fibroma, respectively. Human embryonic kidney (HEK) 293T cells were a kind gift from the
department of Genetics, Erasmus MC, Rotterdam, the Netherlands). All cell lines were cul-
tured in DMEM (Gibco Life Technologies) supplemented with 10% fetal bovine serum, 100
IU/ml penicillin and 100 μg/ml streptomycin at 37˚C in a humidified 5% CO2 atmosphere. All
cell lines were regulary monitored for mycoplasma infection and were subjected to authentica-
tion by performing a short tandem repeat (STR) DNA analyses and matched, when available,
with STR databases. The absence of SUZ12 protein expression in ST88-14 and 90-8TL as
reported by de Raedt et al. [24] was confirmed by Western blotting (S1 Fig). Similarly, the
presence or absence of detectable NF1 protein in the various cell lines was examined (S2 Fig).
RNA isolation
Total RNA was isolated from cell line pellets and fresh frozen tissues using RNAbee (Tel test
Inc., Friendswood, Texas, USA) according to the manufacturer’s instructions. RNA from
BRD4, EZH2 and TOP2A in MPNST
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Table 1. Patient and tumor characteristics.
Paired FFPE tumor samples (n = 9 pairs)
Gender
• Male 6 (66.7%)
• Female 3 (33.3%)
Age at biopsy/resection NF (years)
• Median (range) 28 (5–63)
Age at biopsy/resection MPNST (years)
• Median (range) 27 (14–70)
Plexiform neurofibroma
• Head and neck 1 (11.1%)
• Extremities 3 (33.3%)
• Trunk 5 (55.6%)
MPNST
• Head and neck 1 (11.1%)
• Extremities 4 (44.4%)
• Trunk 4 (44.4%)
Fresh frozen tumor samples
Plexiform neurofibromas (n = 7)
Gender
• Male 4 (57.1%)
• Female 3 (42.9%)
Age at biopsy/resection (years)
• Median (range) 29 (10–63)
Location
• Head and neck 1 (14.3%)
• Extremities 4 (57.1%)
• Trunk 2 (28.6%)
Atypical neurofibromas (n = 4)
Gender
• Male 2 (50%)
• Female 2 (50%)
Age at biopsy/resection (years)
• Median (range) 25.5 (15–43)
Location
• Head and neck -
• Extremities 4 (100%)
• Trunk -
MPNST (n = 11)
Gender
• Male 5 (45.5%)
• Female 6 (54.5%)
Age at biopsy/resection (years)
• Median (range) 36 (12–76)
Location
• Head and neck 3 (27.3%)
• Extremities 3 (27.3%)
• Trunk 5 (45.4%)
MPNST; malignant peripheral nerve sheath tumor. NF; plexiform neurofibroma
https://doi.org/10.1371/journal.pone.0183155.t001
BRD4, EZH2 and TOP2A in MPNST
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FFPE tumor samples (5–6 20 μm sections) was isolated using the RecoverAllTM total nucleic
acid isolation kit (Ambion/Life Technologies). RNA quality and quantity were checked using a
Nanodrop-1000 (Nanodrop Technologies).
Quantitative RT-PCR
cDNA was synthesized from 250 ng of total RNA using TaqMan1 Reverse Transcription
Reagents (ThermoFisher Scientific). The mRNA expression levels of target genes and house-
keepers were determined by real time PCR using TaqMan1 Universal PCR Master Mix and
specific Assay-On-Demand products (ThermoFisher Scientific/Applied Biosystems) using an
ABI 7500 Real-Time PCR machine. The following assays were used EZH2 (Hs01016789_m1),
TOP2A(Hs01032137_m1), BRD4(Hs04188087_m1). Expression of EZH2, TOP2A and BRD4
were normalized using PPIA (Pedersen et al, 2014) (Hs99999904_m1) using the comparative
CT method [25]. Each tumor or cell line RNA sample was measured in duplicate after which
the data were analyzed using SDS software (Applied Biosystems). Statistical significance
(p<0.05) was determined on the normalized expression values of the paired FFPE samples
using a paired Student t-test.
Protein lysates, SDS-PAGE and Western blotting
Total protein was extracted from cells using lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM
NaCl, 10% glycerol, 1% NP-40, 0.5% Na-deoxycholate, 1 mM Na3VO4, 20 mM NaF, 1 mM
Pefabloc) supplemented with a cocktail of protease inhibitors. Protein concentration was
quantified using a Bradford assay (Bio-Rad, Veenendaal, The Netherlands). Equal amounts of
total protein (15–20 μg/lane) were subjected to SDS-PAGE and subsequently transferred to a
PVDF membrane by electroblotting. Remaining protein binding sites of the membrane were
blocked in PBS, 0.05% Tween 20 (PBS/Tween) containing 5% non-fat dried milk. Primary
antibody incubations were carried out in the same buffer with the following primary antibod-
ies: mouse monoclonal anti-EZH2 (1:1000, NCL-L-EZH2, Leica Microsystems;), rabbit mono-
clonal anti-SUZ12 (1:1000, D39F6, Cell Signaling Technology), rabbit polyclonal anti-BRD4
(1:10000, A301-985A100, Bethyl Laboratories, Inc), rabbit monoclonal anti-TOP2A (1:1000,
D10G9, Cell Signaling Technology), rabbit monoclonal anti-NF1 (1:1000, D7R7D, Cell Signal-
ing Technology), rat monoclonal anti-tubulin (1: 4000, YL1/2, Abcam) and mouse monoclonal
anti-β-actin (1:10000, A5441, Sigma-Aldrich). HRP conjugated goat-anti-rabbit, goat-anti-
mouse and goat-anti-rat were used as secondary antibodies. Enhanced chemiluminiscence
(SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific, Rockford, IL, USA)
was used to visualise the signal in a ChemiDoc MP Imager (Bio-Rad, Veenendaal, The Nether-
lands). Protein expression was quantitated using ImageJ, a public domain Java-based image
processing program [26]. Each Western blot was replicated at least three times, depicted are
representative blots.
In vitro cytotoxicity assay
In vitro cytotoxicity of the BET inhibitor JQ1 (BioVision Inc, Milpitas, CA, USA), and the
anthracycline doxorubicin (Pharmachemie, Haarlem, The Netherlands) were determined by a
sulforhodamine B (SRB) assay essentially as described by Keepers et al. [27]. In brief, on day 0
cells were plated in 96-well flat bottom microtiter plates. On day 1 a ten-step, two-fold dilution
series was prepared and added to the cells resulting in a highest concentration of 2500 nM for
JQ1 and 500 ng/ml for doxorubicin. Every dilution was assayed in quadruplicate. After 48–72
hours the assay was terminated, the cells fixed with 10% trichloroacetic acid in PBS for 1 h at
4˚C. After at least four washes with tap water the cells remaining in the wells were stained with
BRD4, EZH2 and TOP2A in MPNST
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0.4% SRB in 1% acetic acid for at least 15 min at RT. Subsequently the unbound stain was
removed by 4 washes in 1% acetic acid. Plates were air-dried and bound stain was dissolved in
150 μl of 10 mM Tris-base. Staining was quantified by measuring the absorbance at 540 nm in
a spectrophotometer. Concentration-response curves were generated and IC50 values were cal-
culated by the use of Deltasoft 3 software.
EZH2 siRNA mediated knockdown
Twentyfour hours prior to transfection the 90-8TL and T265 cell lines were plated in a
24-well plate in duplicate at such a concentration that the next day the wells reach 70–80%
confluency. Cells were transfected with either a EZH2-specific siRNA (Qiagen, FlexiTube
siRNA SI02665166) or a negative control scrambled siRNA (Qiagen, SI03650325) at a concen-
tration of 50 nM using the DharmaFECT1 transfection reagent (Dharmacon/Thermo Scien-
tific) as recommended by the manufacturer. Twentyfour hours post-transfection the medium
was replaced with standard culture medium and cell density as a measure for proliferation was
assessed by SRB staining at 24, 48 and 72 hours after transfection.
Results
Human BRD4 mRNA levels are not increased in MPNST compared to
neurofibromas
In the search for targetable alterations in MPNST Patel et al. reported a potential pathogenic
role of a BET bromodomain family member (Brd4) in an MPNST mouse model. Inhibition of
Brd4, which was found highly upregulated in MPNST, induced increased expression of the
pro-apoptotic molecule Bim inducing apoptosis in MPNST cells and tumor shrinkage [13].
We examined BRD4 mRNA expression by qRT-PCR in a series of nine paired human MPNST
and plexiform neurofibroma FFPE samples, each pair derived from the same patient (Fig 1A).
To rule out that degradation of the total RNA isolated from the archival samples impairs accu-
rate quantitation we also determined BRD4 mRNA levels in a set of fresh frozen plexiform
neurofibromas (n = 7), atypical neurofibromas (n = 4) and MPNST (n = 11) (Fig 1B). Both in
the neurofibroma-MPNST pairs as well as in the fresh frozen samples we did not detect BRD4
overexpression in the MPNST samples (Fig 1A and 1B). The paired sample analyses indicated
significantly higher BRD4 mRNA levels in 6 of the neurofibromas compared to their corre-
sponding MPNST whereas in most fresh frozen samples there was no significant difference in
BRD4 mRNA levels between (atypical) plexiform neurofibromas and MPNSTs. It must be
noted, however, that mRNA levels may not be indicative for protein levels as in most MPNST
cell lines BRD4 mRNA levels were similar but BRD4 protein levels varied considerable (cf. Fig
1C and 1D). To further investigate whether BRD4 can serve as a target for treatment we deter-
mined the sensitivity of our cell line panel consisting of a neurofibroma and 5 MPNST cell
lines, to the BET bromodomain inhibitor JQ1 (Fig 2A). In an in vitro cytotoxicity assay the cell
lines were exposed to increasing concentrations of JQ1 for 72 hours. Most MPNST cell lines
did not display a clearly increased sensitivity to JQ1 compared to the neurofibroma cell line.
The MPNST cell lines sNF96.2, T265 and 90-8TL expressed approximately equal levels of
BRD4 protein and displayed similar sensitivity to JQ1 (Fig 2B). ST88-14 another NF1-derived
MPNST cell line expressed relatively low BRD4 protein levels and was accordingly found less
sensitive to JQ1. In contrast the sporadic MPNST cell line STS26T harbors high levels of BRD4
protein but is relatively insensitive to JQ1. For these cell lines we were not able to calculate
IC50 values (Fig 2B).
BRD4, EZH2 and TOP2A in MPNST
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EZH2 levels are increased in MPNST compared to neurofibromas but do
not affect cellular proliferation
Nuclear EZH2 levels were reported to be induced in MPNST compared to neurofibromas and
normal nerves as measured by immunohistochemistry [15]. Our observations support these
results as the EZH2 mRNA levels were significantly increased in the MPNST samples from 6
out of 9 plexiform neurofibroma/MPNST pairs (Fig 3A). Also in RNA isolated from fresh fro-
zen neurofibroma and MPNST samples EZH2 mRNA levels appeared on average to be 8-fold
higher in MPNST than in (atypical) plexiform neurofibromas (Fig 3B). Similarly, all the
MPNST cell lines displayed relatively high EZH2 mRNA levels compared to the neurofibroma
cell line (Fig 3C). At a protein level, as judged by Western blot, EZH2 also seems more highly
expressed in the MPNST cell lines although it is clear that protein expression and mRNA levels
do not always perfectly match (Fig 3D). Next, we investigated whether EZH2 inhibition exerts
an anti-proliferation activity as was previously reported [15]. Both T265 and 90-8TL MPNST
cells were transiently transfected with an EZH2 siRNA and a scrambled siRNA control for
comparison. EZH2 protein levels were significantly reduced by the EZH2 siRNA treatment at
Fig 1. Expression level of BRD4 in human neurofibroma and MPNST samples and cell lines. (A) qRT-PCR was used to determine mRNA levels
of BRD4 in paired plexiform neurofibroma (NF, blue, n = 9) and MPNST (red, n = 9) formalin-fixed paraffin-embedded tumor samples, each pair being
derived from the same NF1 patient. Asterisk indicates P<0.05. (B) qRT-PCR was used to determine mRNA levels of BRD4 in fresh frozen MPNST (red,
n = 11), plexiform neurofibroma (blue, n = 7) and atypical neurofibroma (grey, n = 4). (C) qRT-PCR was used to determine mRNA levels of BRD4 in a
cell line panel: Hs53.T neurofibroma cell line (blue) and STS26T, sNF96.2, ST88-14, T265 and 90-8TL MPNST cell lines (red) (D) Western blot
displaying BRD4 protein expression in cell line panel and HEK293T. β-actin levels are shown as a loading control.
https://doi.org/10.1371/journal.pone.0183155.g001
BRD4, EZH2 and TOP2A in MPNST
PLOS ONE | https://doi.org/10.1371/journal.pone.0183155 August 15, 2017 7 / 17
BRD4, EZH2 and TOP2A in MPNST
PLOS ONE | https://doi.org/10.1371/journal.pone.0183155 August 15, 2017 8 / 17
48–72 h after transfection (Fig 4A). However, despite the clearly decreased EZH2 levels no sig-
nificant inhibition of cell proliferation was observed (Fig 4B).
Relative high expression of TOP2A in MPNST is associated with
doxorubicin sensitivity
To verify whether TOP2A expression levels are increased in MPNST as was reported in the lit-
erature [9, 10] we determined the TOP2A mRNA levels in our paired FFPE and fresh frozen
plexiform neurofibroma/MPNST sample sets. In both panels TOP2A mRNA expression was
clearly induced in MPNST when compared to the levels detected in plexiform neurofibromas.
In 7 out 9 paired FFPE samples TOP2A levels were significantly increased in the MPNST
Fig 2. Sensitivity of neurofibroma and MPNST cell lines to the BET bromodomain inhibitor JQ1. (A) An in vitro cytotoxicity assay (SRB
assay) was used to determine IC50 values (nM) for the BET bromodomain inhibitor JQ1 of neurofibroma and MPNST cell lines after a 72h
exposure to the drug. Graphs show cell viability as a function of JQ1 concentration. Depicted is the average viability (n = 4) of a representative
experiment. (B) Listing of calculated IC50 values and correlation plot, with BRD4 protein expression levels on the Y-axis and IC50 values for JQ1 on
the X-axis. Pearson correlation coefficient is depicted in the graph.
https://doi.org/10.1371/journal.pone.0183155.g002
Fig 3. Expression level of EZH2 in human neurofibroma and MPNST samples and cell lines. (A) qRT-PCR was used to determine mRNA levels of
EZH2 in paired plexiform neurofibroma (NF, blue, n = 9) and MPNST (red, n = 9) formalin-fixed paraffin-embedded tumor samples, each pair being derived
from the same NF1 patient. Asterisk indicates P<0.05. (B) qRT-PCR was used to determine mRNA levels of EZH2 in fresh frozen MPNST (red, n = 11),
plexiform neurofibroma (blue, n = 7) and atypical neurofibroma (grey, n = 4). (C) qRT-PCR was used to determine mRNA levels of EZH2 in a cell line panel:
Hs53.T neurofibroma cell line (blue) and STS26T, sNF96.2, ST88-14, T265 and 90-8TL MPNST cell lines (red). (D) Western blot displaying EZH2 protein
expression in cell line panel and HEK293T. β-actin levels are shown as a loading control.
https://doi.org/10.1371/journal.pone.0183155.g003
BRD4, EZH2 and TOP2A in MPNST
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samples (Fig 5A). In the fresh frozen sample set TOP2A mRNA levels were on average 24-fold
higher in the MPNST than in the plexiform neurofibromas (Fig 5B). In the cell line panel
TOP2A mRNA levels in the MPNST cell lines were mostly equal or lower than the levels mea-
sured in the neurofibroma cell line Hs53.T, only the MPNST 90-8TL cell line exhibited rela-
tively high TOP2A levels (Fig 5C). At the protein level, however, all MPNST cell lines displayed
markedly higher TOP2A expression than the Hs53.T cells (Fig 5D). To examine whether the
relatively high MPNST TOP2A levels translate into sensitivity to the TOP2A targeting chemo-
therapeutic drug doxorubicin we determined the sensitivity of the cell lines to this drug using
an in vitro cytotoxicity (SRB) assay. All four NF1-associated MPNST cell line (sNF96.2, ST88-
14, T265 and 90-8TL) and one sporadic MPNST cell line (STS26T) were more sensitive to
doxorubicin than the neurofibroma Hs53.T cells, many of them displaying IC50 values of less
than 50 ng/ml (Fig 6A and 6B). A comparison of TOP2A protein expression levels and the cal-
culated IC50 values of the cell lines indicated a correlation, although not very strong, of TOP2A
levels and doxorubicin sensitivity (Fig 6B).
Discussion
Given the limited number of therapeutic options for advanced MPNST patients, the identifica-
tion of novel drug targets and the development of new treatments and treatment strategies is
urgently needed. In this study we analyzed the expression level of three potential drug targets
BRD4, EZH2, and TOP2A in selected human MPNST and neurofibroma samples from the
Erasmus MC tissue bank. Our sample set included both fresh frozen samples and a set of nine
paired FFPE samples consisting of plexiform neurofibromas and MPNST that were resected
from the same patient.
With respect to BRD4, it has been shown that inhibition of this protein profoundly sup-
presses MPNST tumorigenesis and tumor cell growth in a murine MPNST model [13]. To
confirm this putative key role of BRD4 in human MPNST pathogenesis, we evaluated the
expression level of BRD4 in plexiform neurofibromas and MPNST samples. In addition, we
studied the effect of BRD4 modulation by JQ1 on the cell viability of MPNST cell lines. In con-
trast to what has been reported for the MPNST mouse model [13], we did not find evidence
for an increased expression of BRD4 in human MPNST samples when compared to plexiform
neurofibromas. It must be noted, however, that we only examined a limited set tumor samples
due to the rarity of MPNST. Additionally, in order to deal with tumor heterogeneity, it may
be useful to examine multiple biopsies from the same tumor. Nevertheless our analyses of
BRD4 expression, either of FFPE or fresh frozen samples, do not indicate an overexpression in
MPNST. In contrast, previously reported overexpression of EZH2 and TOP2A in MPNST
could be convincingly demonstrated in our sample sets, using similar RT-PCR assays, indicat-
ing RNA quality is good. Alternatively, our inability to confirm BRD4 overexpression in the
human MPNST setting may indicate that data acquired with genetically engineered animal
models cannot always be easily translated to the human situation. It might be that these models
do not recapitulate the full complexity of human cancers and/or there are unrecognized funda-
mental cross-species differences in the process of tumorigenesis [28, 29]. Moreover, BRD4
inhibition by JQ1 treatment in our panel of MPNST cell lines indicated that they were less sen-
sitive to JQ1 than the primary murine skin-derived precursors (Nf1-/-, P53-/-) and MPNST cells
Fig 4. siRNA mediated knockdown of EZH2 and its effect on cell proliferation. (A) Western blot showing
the effect of EZH2 siRNA (si+) or a scrambled control siRNA (si-) on EZH2 protein levels in T265 and 90-8TL
at 48h and 72 h post-transfection. (B) Cell proliferation monitored in time after transfection of T265 and 90-
8TL with EZH2 siRNA (si+) or a scrambled control siRNA (si-). β-actin levels are shown as a loading control.
https://doi.org/10.1371/journal.pone.0183155.g004
BRD4, EZH2 and TOP2A in MPNST
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derived thereof which display IC50 values of< 400 nM [13]. Although Patel et al. did use the
human S462 MPNST cell line they did not present a dose-response curve from which an IC50
value could be deduced making a direct comparison with our results difficult. Likewise Patel
et al. did not validate their findings regarding Brd4 overexpression in clinical tumor samples.
Interestingly, de Raedt and colleagues provided evidence that BRD4 inhibition by JQ1 exerted
only a modest, cytostatic effect on human MPNST cell lines and that only the combination of
JQ1 with PD-901, a MEK-inhibitor, caused a tumor growth inhibition and regression [24].
Zhang et al. demonstrated that EZH2 is overexpressed in MPNST and fulfils a key role in
tumorigenesis [15, 18]. Both downregulation of EZH2 by si/shRNA or pharmacological inhibi-
tion of EZH2 in the S462 (NF1-derived MPNST) and MPNST724 (spontaneous MPNST) cell
lines severely affected cellular proliferation rates, induced apoptosis and interfered with tumor
formation in an MPNST724 xenograft model. We do confirm that EZH2, at least at the mRNA
level, is more abundantly expressed in MPNST than in plexiform neurofibromas. However,
when we examined the consequences of EZH2 downregulation on cellular proliferation in 90-
8TL and T265 we did not observe any inhibitory effect, despite a significant EZH2 knockdown.
It might be that the cell lines used by Zhang et al. respond differently to EZH2 knockdown or
Fig 5. Expression level of TOP2A in human neurofibroma and MPNST samples and cell lines. (A) qRT-PCR was used to determine mRNA levels of
TOP2A in paired plexiform neurofibroma (NF, blue, n = 9) and MPNST (red, n = 9) formalin-fixed paraffin-embedded tumor samples, each pair being
derived from the same NF1 patient. Asterisk indicates P<0.05. (B) qRT-PCR was used to determine mRNA levels of TOP2A in fresh frozen MPNST (red,
n = 11), plexiform neurofibroma (blue, n = 7) and atypical neurofibroma (grey, n = 4). (C) qRT-PCR was used to determine mRNA levels of TOP2A in a cell
line panel: Hs53.T neurofibroma cell line (blue) and STS26T, sNF96.2, ST88-14, T265 and 90-8TL MPNST cell lines (red). (D) Western blot displaying
TOP2A protein expression in cell line panel and HEK293T. β-actin levels are shown as a loading control.
https://doi.org/10.1371/journal.pone.0183155.g005
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inhibition than the NF1-derived MPNST cell lines 90-8TL and T265 that we examined. It may
be that knockdown of EZH2 is compensated for by other members of the PRC2 complex and/
or the related EZH1. Our findings, however, do suggest that EZH2 functions may be depen-
dent on cellular context. Importantly, it was recently reported that a substantial number of
MPNST, irrespective of their origin (NF1-derived, spontaneous or radiation induced) exhibit
an inactivated PRC2 complex due to somatic loss-of-function mutations in SUZ12 and EED
[24, 30, 31]. Both SUZ12 and EED—just as EZH2—are integral parts of the PRC2 complex. It
is not yet known what the consequences of such a PRC2 inactivation are for the remaining
unaffected PRC2 complex subunits like EZH2. Is EZH2 still present in a protein complex
and is EZH2 capable of fulfilling a biological role in this context or on its own? Perhaps the dis-
crepancy between our findings and those of Zhang et al. [15] can be explained by different lev-
els of PRC2 complex inactivation in the cell lines used. Translated to the clinic this would
imply that before targeting EZH2 in the context of MPNST it is imperative to verify whether
the PRC2 complex is in fact inactivated e.g. by determining the absence of H3K27 trimethyla-
tion (H3K27me3) in the tumor tissue. Only MPNST patients that display an active PRC2 com-
plex may benefit from EZH2 inhibition.
The enzyme TOP2A functions in maintaining DNA topology after replication. The cellular
abundance of TOP2A is reported to determine the efficacy of anthracycline based chemother-
apy in various cancers [32–37]. The anthracycline doxorubicin, a widely used anticancer
agent, can interfere with the catalytic cycle of TOP2A either by preventing its binding to DNA
or by trapping TOP2A cleavage complexes and blocking DNA religation generating double
strand DNA breaks [8]. TOP2A levels in MPNST were reported to be upregulated due to
amplification of the TOP2A gene [9, 10]. Our results verified the abundant expression of
TOP2A in MPNST and may explain why doxorubicin is widely used in the treatment of
advanced MPNST patients. Though in general outcomes are poor, some patients may derive
durable benefit from doxorubicin based treatment [7]. When we determined the sensitivity of
our neurofibroma and MPNST cell line panel for doxorubicin we observed that the MPNST
cell lines exhibited the highest sensitivity in agreement with their higher TOP2A levels. Still
the outcome of doxorubicin treatment in the clinic is poor for most MPNST patients perhaps
due to the rapid activation of drug resistance mechanisms that diminish the efficacy of this
chemotherapy.
From this study, we tentatively conclude that the potential for effective therapeutic inter-
vention in MPNST by targeting BRD4, EZH2 and TOP2A individually, is limited. However,
this does not preclude the use of inhibitors in certain subpopulations of patients and/or in
combination therapies. We strongly encourage other research groups to validate our findings
and are in favor of clinical studies involving patients as only these will ultimately prove the
true value of BRD4, EZH2 and TOP2A inhibitors in the MPNST setting. Last but not least fur-
ther investigations are needed into the biology of MPNST to identify additional druggable dis-
ease drivers for novel therapeutic strategies.
Supporting information
S1 Fig. Neurofibroma and MPNST cell lines. (A) Overview of neurofibroma and MPNST
cell lines. (B) Western blot displaying SUZ12 protein expression in neurofibroma and MPNST
Fig 6. Sensitivity of neurofibroma and MPNST cell lines to doxorubucin. (A) An in vitro cytotoxicity assay (SRB assay) was
used to determine IC50 values (ng/ml) for doxorubucin of neurofibroma and MPNST cell lines after a 48h exposure to the drug.
Graphs show cell viability as a function of doxorubucin concentration. Depicted is the average viability (n = 4) of a representative
experiment. (B) Listing of calculated IC50 values and correlation plot, with TOP2A protein expression levels on the Y-axis and IC50
values for doxorubicin on the X-axis. Pearson correlation coefficient is depicted in the graph.
https://doi.org/10.1371/journal.pone.0183155.g006
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cell line panel and HEK293T. β-actin levels are shown as a loading control.
(TIF)
S2 Fig. NF1 expression in neurofibroma and MPNST cell lines. Western blot displaying
NF1 protein expression in neurofibroma and MPNST cell line panel and the non-small cell
lung cancer cell lines NCI-H460 and NCI-H1299. Tubulin levels are shown as a loading con-
trol.
(TIF)
S3 Fig. BRD4 protein expression in neurofibroma and MPNST cell line panel. Uncropped
blot related to Fig 1D.
(TIF)
S4 Fig. EZH2 protein expression in neurofibroma and MPNST cell line panel. Uncropped
blot related to Fig 3D.
(TIF)
S5 Fig. EZH2 protein expression upon siRNA mediated knockdown. Uncropped blot
related to Fig 4A.
(TIF)
S6 Fig. TOP2A and SUZ12 protein expression in neurofibroma and MPNST cell line
panel. Uncropped blot related to Fig 5D (TOP2A) and S1 Fig. (SUZ12).
(TIF)
S1 Table. Ct and normalized expression values of individual data points. Excel file contain-
ing RT-PCR data related to Fig 1A–1C; Fig 3A–3C and Fig 5A–5C.
(XLSX)
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